Aids Research and Human Retroviruses
-
Publication Venue For
-
Designing Dual Compartment HIV Prevention Products: Women's Sensory Perceptions and Experiences of Suppositories for Rectal and Vaginal Use..
38:601-610.
2022
-
Considerations for Increasing Racial, Ethnic, Gender, and Sexual Diversity in HIV Cure-Related Research with Analytical Treatment Interruptions: A Qualitative Inquiry..
38:50-63.
2022
-
Reasons People Living with HIV Might Prefer Oral Daily Antiretroviral Therapy, Long-Acting Formulations, or Future HIV Remission Options..
36:1054-1058.
2020
-
The Role of Volume in the Perceptibility of Topical Vaginal Formulations: User Sensory Perceptions and Experiences of Heterosexual Couples During Vaginal Sex..
36:1059-1070.
2020
-
The Dose Response: Perceptions of People Living with HIV in the United States on Alternatives to Oral Daily Antiretroviral Therapy..
36:324-348.
2020
-
Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection.
36:13-18.
2020
-
Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor–Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance.
34:343-346.
2018
-
Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection..
34:111-122.
2018
-
Short Communication: Potential Risk of Replication-Competent Virus in HIV-1 Env-Pseudotyped Virus Preparations..
33:368-372.
2017
-
Perceptibility and the "Choice Experience": User Sensory Perceptions and Experiences Inform Vaginal Prevention Product Design..
32:1022-1030.
2016
-
Short communication: feasibility and acceptability of developing a multisite clinical cohort of transgender people with HIV infection..
31:870-872.
2015
-
Reflections: A Case for Intersectional Approaches in HIV Research..
31:669-670.
2015
-
Mass Transport Theory Improves Compartmental PK Modeling of Microbicides and Helps Guide Product Science and Development..
30 Suppl 1:A147.
2014
-
Tenofovir diphosphate concentrations in human vaginal stroma after different dosage regimens with a vaginal gel: a modeling approach..
30 Suppl 1:A258-A259.
2014
-
Transport and transport properties of tenofovir from microbicide gels into vaginal tissue: analysis using Raman spectroscopy..
30 Suppl 1:A59-A60.
2014
-
Designing preclinical perceptibility measures to evaluate topical vaginal gel formulations: relating user sensory perceptions and experiences to formulation properties..
30:78-91.
2014
-
Relationships Among HIV Infection, Metabolic Risk Factors, and Left Ventricular Structure and Function.
29:1151-1160.
2013
-
Comparison of Population and 454 “Deep” Sequence Analysis for HIV Type 1 Tropism Versus the Original Trofile Assay in Non-B Subtypes.
29:979-984.
2013
-
Identification of personal lubricants that can cause rectal epithelial cell damage and enhance HIV type 1 replication in vitro..
27:1019-1024.
2011
-
DNA-MVA vaccine protection after X4 SHIV challenge in macaques correlates with day-of-challenge antiviral CD4+ cell-mediated immunity levels and postchallenge preservation of CD4+ T cell memory..
24:505-519.
2008
-
Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates..
24:271-281.
2008
-
Comparison of methods to detect recent HIV type 1 infection in cross-sectionally collected specimens from a cohort of female sex workers in the Dominican Republic..
23:1475-1480.
2007
-
Immunogenicity in macaques of the clinical product for a clade B DNA/MVA HIV vaccine: elicitation of IFN-gamma, IL-2, and TNF-alpha coproducing CD4 and CD8 T cells..
23:1555-1562.
2007
-
Predicting CD4 lymphocyte count.
23:1230-1236.
2007
-
Predicting CD4 lymphocyte count <200 cells/mm(3) in an HIV type 1-infected African population..
23:1230-1236.
2007
-
Identification of CRF34_01B, a second circulating recombinant form unrelated to and more complex than CRF15_01B, among injecting drug users in northern Thailand..
23:829-833.
2007
-
Induction of a nonproductive conformational change in gp120 by a small molecule HIV type 1 entry inhibitor..
23:28-32.
2007
-
Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults..
22:678-683.
2006
-
Capric acid and hydroxypropylmethylcellulose increase the immunogenicity of nasally administered peptide vaccines..
22:558-568.
2006
-
Comparative evaluation of simian, simian-human, and human immunodeficiency virus infections in the pigtail macaque (Macaca nemestrina) model..
22:580-588.
2006
-
Short communication: characteristics of effective immune control of simian/human immunodeficiency virus in pigtail macaques..
22:27-32.
2006
-
Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus..
21:629-643.
2005
-
Immunodominance and cross-reactivity of B5703-restricted CD8 T lymphocytes from HIV type 1 subtype C-infected Ethiopians..
21:239-245.
2005
-
Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies..
21:58-67.
2005
-
Longitudinal assessment of immune response and viral characteristics in HIV-infected patients with prolonged CD4(+)/viral load discordance..
21:13-16.
2005
-
Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials..
21:68-81.
2005
-
Complete genome analysis of one of the earliest SIVcpzPtt strains from Gabon (SIVcpzGAB2)..
20:1377-1381.
2004
-
DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime..
20:1335-1347.
2004
-
Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations..
20:1269-1281.
2004
-
An inducible HIV type 1 gp41 HR-2 peptide-binding site on HIV type 1 envelope gp120..
20:836-845.
2004
-
Multiprotein HIV type 1 clade B DNA and MVA vaccines: construction, expression, and immunogenicity in rodents of the MVA component..
20:645-653.
2004
-
The changing molecular epidemiology of HIV type 1 among northern Thai drug users, 1999 to 2002..
20:465-475.
2004
-
Protective immunity to SIV challenge elicited by vaccination of macaques with multigenic DNA vaccines producing virus-like particles..
20:425-434.
2004
-
Effects of human immunodeficiency virus type 1 infection on CCR5 and CXCR4 coreceptor expression on CD4 T lymphocyte subsets in infants and adolescents..
20:305-313.
2004
-
A cluster of HIV type 1 subtype C sequences from Ethiopia, observed in full genome analysis, is not sustained in subgenomic regions..
19:1125-1133.
2003
-
Gp120-alum boosting of a Gag-Pol-Env DNA/MVA AIDS vaccine: poorer control of a pathogenic viral challenge..
19:891-900.
2003
-
IL-12/GM-CSF coadministration in an SIV DNA prime/protein boost protocol enhances Gag-specific T cells but not virus-specific neutralizing antibodies in rhesus macaques..
19:883-890.
2003
-
Codon usage optimization of HIV type 1 subtype C gag, pol, env, and nef genes: in vitro expression and immune responses in DNA-vaccinated mice..
19:817-823.
2003
-
A new circulating recombinant form, CRF15_01B, reinforces the linkage between IDU and heterosexual epidemics in Thailand..
19:561-567.
2003
-
Detection of mucosal antibodies in HIV type 1-infected individuals..
18:1291-1300.
2002
-
Analysis of partial pol and env sequences indicates a high prevalence of HIV type 1 recombinant strains circulating in Gabon..
18:1103-1116.
2002
-
Precise mapping of recombination breakpoints suggests a common parent of two BC recombinant HIV type 1 strains circulating in China..
18:1135-1140.
2002
-
Addition of cyclophosphamide to antiretroviral therapy does not diminish the cellular reservoir in HIV-infected persons..
18:535-543.
2002
-
Increased replication of non-syncytium-inducing HIV type 1 isolates in monocyte-derived macrophages is linked to advanced disease in infected children..
18:353-362.
2002
-
Resistance to neutralizing antibody and expanded coreceptor usage are associated with human immunodeficiency virus type 1 isolates derived from chimpanzees with pathogenic infections..
17:1705-1714.
2001
-
Thymopoiesis in HIV-infected adults after highly active antiretroviral therapy..
17:1635-1643.
2001
-
Immunologic and virologic analyses of an acutely HIV type 1-infected patient with extremely rapid disease progression..
17:1333-1344.
2001
-
Molecular characterization of a highly divergent HIV type 1 isolate obtained early in the AIDS epidemic from the Democratic Republic of Congo..
17:1217-1222.
2001
-
Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins..
17:829-835.
2001
-
Evidence of two distinct subsubtypes within the HIV-1 subtype A radiation..
17:675-688.
2001
-
Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1..
16:2019-2035.
2000
-
Monoclonal antibodies that bind to the core of fusion-active glycoprotein 41..
16:2037-2041.
2000
-
Identification of highly conserved and broadly cross-reactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored HIV vaccines..
16:1433-1443.
2000
-
Presence of diverse human immunodeficiency virus type 1 viral variants in Cameroon..
16:1319-1324.
2000
-
Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: a meta-analysis. HIV Surrogate Marker Collaborative Group..
16:1123-1133.
2000
-
Phylogenetic analysis of protease and transmembrane region of HIV type 1 group O..
16:1075-1081.
2000
-
A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group..
16:907-919.
2000
-
Effect of highly active antiretroviral therapy and thymic transplantation on immunoreconstitution in HIV infection..
16:403-413.
2000
-
Recombinant Bacillus Calmette-Guerin as a Potential Vector for Preventive HIV Type 1 Vaccines.
16:91-98.
2000
-
Oropharyngeal candidiasis in patients with HIV: suggested guidelines for therapy..
15:1619-1623.
1999
-
Primary isolate neutralization by HIV type 1-infected patient sera in the era of highly active antiretroviral therapy..
15:1563-1571.
1999
-
Diagnosis and treatment of oropharyngeal candidiasis in patients infected with HIV: a critical reassessment..
15:1405-1412.
1999
-
Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors..
15:1219-1228.
1999
-
Partial resistance to infection by R5X4 primary HIV type 1 isolates in an exposed-uninfected individual homozygous for CCR5 32-base pair deletion..
15:1201-1208.
1999
-
Combined systemic and mucosal immunization with microsphere-encapsulated inactivated simian immunodeficiency virus elicits serum, vaginal, and tracheal antibody responses in female rhesus macaques..
15:1121-1136.
1999
-
MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group..
15:921-930.
1999
-
Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida..
15:633-645.
1999
-
Effect of complement consumption by cobra venom factor on the course of primary infection with simian immunodeficiency virus in rhesus monkeys..
15:195-202.
1999
-
HIV type 1 subtypes in Malaysia, determined with serologic assays: 1992-1996..
14:1687-1691.
1998
-
Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41..
14:1271-1280.
1998
-
Herpesvirus saimiri transformation of HIV type 1 suppressive CD8+ lymphocytes from an HIV type 1-infected asymptomatic individual..
14:521-531.
1998
-
Oral SIV, SHIV, and HIV type 1 infection..
14 Suppl 1:S97-103.
1998
-
Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions..
14:151-155.
1998
-
New perspectives on AIDS vaccine development: Editorial.
14.
1998
-
Diversity of full-length subtype E HIV type 1 env sequences in early seroconvertors from northern Thailand..
13:1439-1441.
1997
-
Intranasal immunization is superior to vaginal, gastric, or rectal immunization for the induction of systemic and mucosal anti-HIV antibody responses..
13:945-952.
1997
-
Identification of a synthetic peptide that mimics an HIV glycoprotein 120 envelope conformational determinant exposed following ligation of glycoprotein 120 by CD4..
13:657-664.
1997
-
The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. The DATRI 004 Study Group. Division of AIDS Treatment Research Initiative..
13:305-315.
1997
-
HIV type 1 vaccine-induced cytotoxic T cell responses in phase I clinical trials: detection, characterization, and quantitation..
13:211-216.
1997
-
A model for alignment of Env V1 and V2 hypervariable domains from human and simian immunodeficiency viruses..
12:1169-1178.
1996
-
Antibodies against retroviral proteins and nuclear antigens in a subset of idiopathic CD4+ T lymphocytopenia patients..
12:931-940.
1996
-
Perspective: research highlights at the Duke University center for AIDS research. Immunoreconstitution in HIV infection: the role of the thymus..
12:751-755.
1996
-
Potent inhibition of HIV type 1 infection of mononuclear phagocytes by synthetic peptide analogs of HIV type 1 protease substrates..
12:777-782.
1996
-
Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group..
12:683-693.
1996
-
Sequences and phylogenetic analysis of the nef gene from Thai subjects harboring subtype E HIV-1..
12:557-560.
1996
-
DNA vaccines..
12:455-457.
1996
-
Studies of complement-activating antibodies in the SIV/macaque model of acute primary infection and vaccine protection..
11:963-970.
1995
-
Inhibition of HIV type 1 infection of mononuclear phagocytes by anti-CD44 antibodies..
11:541-546.
1995
-
HIV type 1 V3 region primer-induced antibody suppression is overcome by administration of C4-V3 peptides as a polyvalent immunogen..
11:211-221.
1995
-
Activation of interleukin 4- and interleukin 6-secreting cells by HIV-specific synthetic peptides..
11:97-105.
1995
-
Absence of recoverable infectious virus and unique immune responses in an asymptomatic HIV+ long-term survivor..
10:1703-1711.
1994
-
Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network..
10:1713-1723.
1994
-
Ultraviolet-light-inactivated Cas-Br-M murine leukemia virus induces a protective CD8+ cytotoxic T lymphocyte response in newborn mice..
10:1695-1702.
1994
-
A novel method for detection and ex vivo expansion of HIV type 1-specific cytolytic T lymphocytes..
10:1427-1431.
1994
-
Genetic variation of HIV type 1 in four World Health Organization-sponsored vaccine evaluation sites: generation of functional envelope (glycoprotein 160) clones representative of sequence subtypes A, B, C, and E. WHO Network for HIV Isolation and Characterization..
10:1359-1368.
1994
-
HIV-1 sequence subtype D in the United States..
10:625-627.
1994
-
1993 Annual Meeting of the Laboratory of Tumor Cell Biology: Introduction.
10.
1994
-
Conference on advances in AIDS vaccine development--1993. Summary: correlates of HIV Immunity Working Group..
10 Suppl 2:S171-S176.
1994
-
Dicistronic polioviruses as expression vectors for foreign genes..
10 Suppl 2:S57-S60.
1994
-
Seroprevalence and seroincidence of HIV-1 in injection drug users using the VA system..
10 Suppl 2:S215-S217.
1994
-
CD8+ T lymphocyte-mediated inhibition of HIV-1 long terminal repeat transcription: a novel antiviral mechanism..
9:1079-1086.
1993
-
INDUCTION OF BROADLY CROSS-REACTIVE HIV NEUTRALIZING ANTIBODIES IN PRIMATES USING A PRIME-BOOST REGIMEN OF HYBRID SYNTHETIC GP120 ENVELOPE PEPTIDES.
9:S29-S29.
1993
-
Genetic typing of HIV-2 from a Senegalese/German heterosexual transmission..
9:703-704.
1993
-
The impact of HIV-1 infection on phenotypic and functional parameters of cellular immunity in chimpanzees..
9:647-656.
1993
-
HIV-1 infection stimulates T cell invasiveness and synthesis of the 92-kDa type IV collagenase..
9:513-518.
1993
-
Detection of anti-human cell antibodies in sera from macaques immunized with whole inactivated virus..
8:1641-1652.
1992
-
CTL cross reactivity between HIV strains..
8:1369-1371.
1992
-
HIV-1 intrapatient sequence diversity in the immunogenic V3 region..
8:1461-1465.
1992
-
Inactivated whole SIV vaccine in macaques: evaluation of protective efficacy against challenge with cell-free virus or infected cells..
8:1501-1505.
1992
-
Specific activation strategies for amplification of low CTL signals..
8:1373.
1992
-
In vitro assays for detecting neutralizing and fusion-inhibiting antibodies to SIVMAC251..
7:713-720.
1991
-
HIV-1 neutralizing monoclonal antibodies induced by a synthetic peptide..
6:1115-1123.
1990
-
Editorial.
6.
1990
-
INDUCTION OF NEUTRALIZING ANTI-HIV ANTIBODIES IN GOATS AND RHESUS-MONKEYS WITH HYBRID SYNTHETIC PEPTIDES (T1-SP10) FROM HIV GP120 THAT CONTAIN EPITOPES RECOGNIZED BY BOTH T-CELLS AND B-CELLS.
6:38-39.
1990
-
Introduction.
6:1.
1990
-
In vitro evaluation of mismatched double-stranded RNA (ampligen) for combination therapy in the treatment of acquired immunodeficiency syndrome..
5:193-203.
1989
-
Cellular immune response to viral peptides in patients exposed to HIV..
4:259-267.
1988
-
Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein..
4:187-197.
1988
-
Detection of HIV-1 neutralizing antibodies by a simple, rapid, colorimetric assay..
4:63-69.
1988
-
Anti-GP 120 antibodies from HIV seropositive individuals mediate broadly reactive anti-HIV ADCC..
3:409-422.
1987
-
Evidence that mannosyl residues are involved in human immunodeficiency virus type 1 (HIV-1) pathogenesis..
3:265-282.
1987
-
Prospects for development of a vaccine against HTLV-III-related disorders..
3 Suppl 1:197-206.
1987
-
Transmission of HIV by antigen presenting cells during T-cell activation: prevention by 3'-azido-3'-deoxythymidine..
3:87-94.
1987
-
Near full-length clones and reference sequences for subtype C isolates of HIV type 1 from three different continents..
17:161-168.
2001
-
HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group..
15:115-132.
1999
-
New insights into the role of host cell proteins in antiviral vaccine protection..
11:1429-1431.
1995
-
Assessment of the Frequency of VRC01 Class Naive B Cells in Different Populations That Can Potentially Engage an HIV CD4 Binding Site Immunogen
2018
-
Bridging Vaccine-induced Antibody Responses in Rabbit and Rhesus Macaque Animal Models
2018
-
Characterizing Env-specific Monoclonal Antibodies Isolated From US and Malawian HIV-infected Non-transmitting and Transmitting Women
2018
-
Chimpanzee SIV Envelope-derived Trimer Guides an Immunofocused HIV Cross-neutralizing Ab Response in V2-apex bnAb UCA Expressing Knock-in Mice
2018
-
Co-administration of 3 Doses of DNA/Protein Improves Antibody Responses to a Prime-boost Approach, but Needle-free Injection of DNA Shows No Benefit
2018
-
Cross-clade ADCC Activities in Human Volunteer Sera Elicited by a Polyvalent DNA Prime-protein Boost HIV Vaccine DP6-001
2018
-
DNA-prime Induces Higher Magnitude Humoral Responses Than ALVAC-prime in HIV Vaccine Regimens With the Same Protein Boost
2018
-
Delayed and Repetitive Boosting of RV144 Vaccinees Improves Antiviral Immunity Associated With Correlates of HIV-1 Infection Risk
2018
-
Dual Maturation Pathways from the Unmutated Common Ancestor of HIV-1 Envelope Broadly Neutralizing Antibodies Overcome Glycan Barriers
2018
-
Expansion of VH1-2*02 Env-specific B Cells in a Non-neutralizing HIV-1 Env Vaccine Regimen
2018
-
Germline-targeting and Reverse Engineering to Elicit CH235.12 Lineage bNAbs
2018
-
Glycoengineering HIV-1 Env Creates "Supercharged" and "Hybrid" Glycans to Increase Neutralizing Antibody Potency, Breadth and Saturation
2018
-
HIV Neutralizing Antibodies Induced by Native-like Envelope Trimers Incorporated Into a Rhabdoviral Vector Vaccine
2018
-
HVTN114: A Phase 1 Trial to Evaluate Late Boosts With AIDSVAX B/E of Participants Previously Vaccinated With MVA/HIV62B in DNA/MVA or MVA Regimens
2018
-
Higher HIV Neutralization Breadth in Young Children Than in Chronically Infected Adults
2018
-
Immune Responses to PENNVAX-GP (R) HIV DNA Vaccine Plus IL-12 Are Equivalent or Superior When Delivered by Intradermal vs. Intramuscular Electroporation
2018
-
Impact of Vaccine Regimen on Vaccine-induced Antibody Durability
2018
-
Increase in Env-specific Binding Antibody and CD4+T Cell-responses After Month 30 Boost of gp120/MF59 Delivered Alone or With ALVAC-HIV
2018
-
Increased Breadth of T-cell Responses After Mosaic HIV Vaccination in Humans (HVTN 106)
2018
-
Induction of Neutralizing Antibodies Against Autologous Viruses in HIV-1 Infected Pregnant Women Immunized With a gp120/160 Vaccine
2018
-
Macaque SHIV Induction of 2G12-like Broadly Neutralizing Antibodies
2018
-
Mechanistic Insights Into Vaccine Induction of V2 Apex-directed, Heterologous Tier 2 Neutralizing Responses in CH103 UCA Knock-in Mice
2018
-
Neutralization Potency Can Account for the Majority of Antibody-mediated Protection Observed in ex vivo Vaginal Explant Models of Early HIV Infection
2018
-
Neutralizing and ADCC Activity of Anti-HIV-1 Antibodies Against Acute Subtype C Envs: Implications for Prevention and Treatment of HIV-1 Infection
2018
-
New SHIV Models of bNAb Elicitation and Env-Ab Coevolution
2018
-
Outcomes for PrEP Users in the Southern US: Persistence and STIs
2018
-
Primary Analysis of TRAVERSE: A Phase 1/2a Study to Assess Safety/Tolerability and Immunogenicity of 2 Different Prime/Boost HIV Vaccine Regimens
2018
-
Prolonged Intervals Between Boosts Induces High Magnitude Transient V2-specific Functional Antibodies That Inhibit the Binding of V2 to alpha 4 beta 7 Integrin
2018
-
Recognition and Elimination of HIV-1-infected Cells by ADCC-mediating mAbs for Prevention and Treatment of HIV-1 Infection
2018
-
Safety and Immunogenicity of a pDNA Clade B Env Prime, rVSV Clade C Env Boost HIV-1 Vaccination Regimen in a Phase 1 Clinical Trial
2018
-
Structural Basis for A32-like Epitopes Involved in ADCC Response of the RV114 Vaccine Trial
2018
-
Targeted Selection of an Improbable HIV-1 Antibody Mutation Critical for Broadly Neutralizing Reactivity With a Designed Immunogen
2018
-
Tetravalent Janssen Mosaic Ad26/Protein HIV Vaccine Shows Increased Clade C Env-specific CD4+T-cell and Antibody Responses Versus Trivalent Vaccine
2018
-
Therapeutic Vaccination With a Combination of IDLV-SIV-Gag and IDLV-PGT121 Results in Prolonged Virus Control in Chronically SHIV-infected Macaques
2018
-
V1V2 IgG and Antibody Fc Effector Functions in a Subtype C ALVAC-HIV and Bivalent Subtype C gp120/MF59 HIV-1 Vaccine Trial in South Africa
2018
-
Vaccine Induction of V2 Apex-directed, Cross-reactive Neutralizing Antibodies in CH01 UCA "HC Only" Knock-in Mice
2018
-
Vaccine-induced Activation of Inflammasome in Classical Monocytes and Th2 Cell Responses Correlates With Decreased Risk of SIVmac251 Acquisition
2018
-
Comparing Different Priming Strategies to Optimize HIV Vaccine Antibody Responses: Results from HVTN 096/EV04 (NCT01799954)
2016
-
DNA and Protein Co-delivery Vaccines Using TLR-4-based Adjuvants Induce Potent Immune Responses Able to Delay Heterologous SIV Acquisition
2016
-
DNA/MVA HIV Vaccine Producing Virus-like Particles (VLPs) Is Well-tolerated and Induces Durable Functional Antibodies (Abs) in HVTN 094
2016
-
Deterministic Compartment PK Model for Rectal Tenofovir (TFV) Delivery by an Enema
2016
-
Deterministic Compartmental Pharmacokinetic Model for an Intravaginal Ring (IVR)
2016
-
EV06 Trial: Modulation of the Immunogenicity of the DNA-HIV-PT123 and AIDSVAX (R) B/E combination HIV vaccine in adult Ugandans by S. mansoni Infection
2016
-
Effects of gp140 Protein Booster Immunizations to DNA/MVA SHIV Vaccine on Immunogenicity and Protection against Intravaginal Tier-2 SHIV Challenges
2016
-
Features of Recently Transmitted HIV-1 Clade C Viruses That Impact Antibody Recognition: Implications for Active and Passive Immunization
2016
-
HIV-1 MPER-directed Broadly Neutralizing Antibodies from an Acute-infection Cohort RV217 Subject
2016
-
Infant Peripartum Transmitted-founder HIV-1 Variants are Resistant to Autologous Maternal Plasma Neutralization
2016
-
Initiation of Neutralizing Antibody B Cell Lineages by HIV Vaccine Candidates
2016
-
MVA-expressed gp140 Boosts More Durable V1/V2 and gp120 Antibody Responses than gp120 Protein in Alum
2016
-
Measuring Sensory Experiences Elicited by Product Properties During Receptive Anal Sex: Implications for Prevention Design and Marketing
2016
-
Mucin-binding IgG: Characterizing a Novel Antibody Effector Function and Discovery of a New Fc Receptor
2016
-
Overview of Humoral and Cellular Immune Responses to HIV Vaccination
2016
-
Partial Protection from Intravenous Challenge by an Integration-defective SIV Vaccine
2016
-
Prevention of Vaginal Transmission of Simian-Human Immunodeficiency Virus (SHIV) in Rhesus Monkeys by Small-molecule CD4-mimetic Compounds
2016
-
Protection from Rectal SHIV Infection Induced by Mucosal Vaccination with a Replication-competent VSV-HIV Chimera Delivering Env Trimers
2016
-
Role of Adjuvants in Enhancing Durability of HIV Vaccine Responses by Inducing Potent Germinal Centers and Plasma Cell Responses
2016
-
Selective Activation of VRC01-class Germline Antibodies in Knock-in Mice with Diverse Precursor Repertoires
2016
-
Synthetic Biocompatible Polymers Are an Effective Delivery Platform That Elicits Potent Antibody Responses Against HIV-1 Glycopeptide Immunogens
2016
-
The Relationship between Immune Responses to Tetanus Vaccine, Hepatitis B Vaccine and a Pox-protein HIV Vaccine Regimen
2016
-
African Early Infection Cohort as a Platform for Vaccine Discovery: The IAVI Protocol C Experience
2014
-
An HIV DNA Vaccine Delivered by Electroporation and Boosted by rVSV HIV-1 Gag Is Safe and Immunogenic in Healthy HIV-uninfected Adults
2014
-
Antiretroviral Pre-exposure Prophylaxis and Risk of Decreased Glomerular Filtration Rate among HIV Uninfected Men and Women
2014
-
DuoGel™: The Development of A Multi-drug Dual Chamber Vaginal/Rectal Anti-HIV Microbicide Gel
2014
-
HVTN 097: Evaluation of the RV144 Vaccine Regimen in HIV Uninfected South African Adults
2014
-
Immune Correlates Identified in the RV144 Vaccine Efficacy Trial Impact HIV-1 Acquisition Only in the Presence of Certain HLA Class II Genes
2014
-
Microbicide-vaccine Combination Provides Significant Protection against Vaginal SHIV-162P3 Challenge in Cynomolgous Monkeys
2014
-
No Increase in Activated T Cells and Limited Increase in Adenovirus-specific T Cells in Colon and Rectal Mucosa Following HIV-1 DNA/rAd5 Immunization
2014
-
Plasmablast Phenotype and Mucosal Antibodies to V2 in Vaccine-induced Protection Against SIVmac251
2014
-
Utilizing Mucin-tethered HIV IgG to Enhance HIV Vaccine Function
2014
-
A Combined Saavi MVA-C and Novartis Gp140 Env Protein Vaccine Boost Elicits Robust HIV Cellular and Humoral Responses in a Nonhuman Primate Model
2013
-
A Late Third HIV-MVA Vaccination Boosted Strong and Potent Immune Responses in Tanzanian Volunteers Previously Immunized with HIV-DNA and HIV-MVA
2013
-
A Single Immunization with Integrase Defective Lentiviral Vector Expressing gp140 Induces Persistent and Functional Immune Response in Rhesus Monkeys
2013
-
Alum and MF59, in Combination with ALVAC-SIV and Gp120 Vaccines Recruit Functionally Different NK Cells to the Gut of Vaccinated Rhesus Macaque
2013
-
Antibody Repertoire Induced by the Multiclade (Env A, B, C) HIV-1 DNA Prime, rAd5 Boost VRC Vaccine
2013
-
Association of Fc gamma RIIC Polymorphism with Vaccine Efficacy and Correlates of HIV-1 Infection Risk in RV144
2013
-
Boosting Antibody Responses with gp140 Protein Two Years After DNA/MVA Priming: Results from the HVTN 073E Phase I Vaccine Trial
2013
-
Combined Mucosal and Systemic C.1086 Envelope Immunization of Lactating Monkeys Induces Potent IgA and Functional IgG Antibody Responses in Milk
2013
-
Comparable Antigenicity and Immunogenicity of Multimeric Forms of a Novel, Acute HIV-1 Subtype C Gp145 Envelope for Clinical Development
2013
-
Comparative Evaluation of Assays for Fc Receptor-Mediated Antibody Effector Functions Targeting HIV-1
2013
-
Development of an Early Stage Investigator Scholar Program for Preclinical Researchers
2013
-
Distinct VH Gene Usage and HIV Envelope Specificity of Colostrum and Peripheral B Cell Monoclonal Antibodies of HIV-Infected, Lactating African Women
2013
-
Eliminating Autoreactivity of Variants of Antibody VRC07 by Glycan Masking
2013
-
Engineering a Next Generation VRC01-Like Antibody with Improved In Vitro and In Vivo Function
2013
-
Env Binding to the alpha 4 beta 7 Integrin Complex Is Not a General Property of Most HIV-1 Variants
2013
-
Exogenous Expression of HIV-1 Envelope Glycoprotein Trimer in Suspension Culture-Adapted HEK293 and CHO-K1 Cells
2013
-
Genetic and Immunological Evidence for a Role of Env-V3 Antibodies in the RV144 Trial
2013
-
HIV-1 Specific Binding Antibody Titres in Blood Predict Detection in the Female Genital Tract in Women Who Became Infected in the CAPRISA 004 Microbicide
2013
-
HLA Class II Genes Interact with the Immune Correlates from the RV144 Vaccine Efficacy Trial and Impact HIV-1 Acquisition
2013
-
HVTN 505: Efficacy of a Multi-Gene DNA Prime/Recombinant Adeno 5 (rAd5) Vector Boost Vaccine in Men & Transgender Women (TGW) Who Have Sex with Men
2013
-
Heterogeneity of Anti-V2 ADCC Ab Responses and Implications for Vaccine Development
2013
-
High Affinity Recognition of Synthetic Glycopeptides by HIV-1 gp120 V1V2 Loop Broadly Neutralizing Antibodies and Their Unmutated Common Ancestors
2013
-
Human HIV-1 Vaccine Induced Antibody Durability and Env IgG3 Responses
2013
-
In Vivo Targeting of HIV Gag to Dendritic Cells Given with Poly ICLC Is Safe and Induces Durable CD4 T Cell and B Cell Responses in Healthy Volunteers
2013
-
Increased HIV-1 Immunogenicity of Replication Competent NYVAC
2013
-
Intestinal Commensal Bacteria Shape the Pre-transmission Antibody Repertoire to HIV-1 Infection
2013
-
Isolation and Characterization of an Autoreactive CD4bs Broad Neutralizing Antibody from a Chronic HIV-1 Controller with Systemic Lupus Erythematosus
2013
-
Isolation of mAbs from Sorted Single B Cells by RT/PCR for Analysis of B Cell Responses to HIV-1 MPER Epitope in Vaccinated Rhesus Macaques
2013
-
Lipid Components in MPER-Based Immunization Regimens Are Critical for Inducing Broadly Neutralizing Antibody Responses in 2F5 and 4E10 Knockin Mice
2013
-
MF59 and ALUM, in Combination with an ALVAC-SIV/gp120 Vaccine, Induce Plasmablasts that Differ in the Expression of Homing Markers
2013
-
Multiclade E-DNA Prime Enhances the Functional Antibody Response Induced by a Recombinant gp120 Boost in Non-human Primates
2013
-
Multiple Pathways of HIV-1 Autologous Neutralizing Antibodies Cooperate to Drive CD4 Binding Site Broadly Neutralizing Antibody Responses
2013
-
Optimization of Systemic and Mucosal Immune Responses to SIV and HIV-1 Antigens Using Different Protocols of DNA and Protein Immunization in Macaques
2013
-
Phylogenetic Conservation of a Dominant Antibody Light Chain HIV Env V2 Binding Motif in Human and rhesus Macaque Antibodies
2013
-
Priming with Adenovirus26 Vaccines Affects ALVAC-SIV/gp120 Vaccine Efficacy Tested in a SIVmac251 Challenge Model Performed One-Month Post-Vaccination
2013
-
Protection from SIVmac251 Acquisition by an ALVAC/SIV/gp120 Regimen Is Not Improved by the Increase of Anti-Envelope Antibodies and T Cell Responses
2013
-
Rhesus Full Length Single Chain (rhFLSC) Protects Rhesus Macaques from Heterologous Intrarectal Challenge with Multiple Low Doses of SHIV162P3
2013
-
Structural Analysis of the Unmutated Common Ancestor Antibodies of the HIV Envelope V2 Antibodies CH58 and CH59 Derived from RV144 Vaccinees
2013
-
Systemic IgG and IgA Responses to gp70V1V2 and C1 in HIV-Infected Elite Controllers Versus Controllers and Noncontrollers on HAART
2013
-
Vaccine Induced Epitope Specific Antibodies to the SIV Envelope Are Distinct from Those Induced to the HIV-1 Envelope
2013
-
HIV-1 gp120 Vaccination Elicits a Robust and Durable Anti-V1/V2 IgG Response and Yet No HIV-1 Env-Specific IgA Response in HIV-Exposed Infants
2013
-
2F5-like Cross-Reactive HIV-1-Neutralizing Monoclonal Antibodies with Low Number of Somatic Mutations
2011
-
A DNA Prime/Protein Boost Vaccine Leads to Higher B-Cell Responses than a Vector Prime/Protein Boost or DNA Prime/Vector Boost Regimens
2011
-
ADCC Titers to HIV-Infected Cells Are Detectable in the Majority of Vaccine Recipients in the RV144 Trial
2011
-
DNA and Protein Vaccination Confers Protection Upon Mucosal Challenge with Heterologous SIVsmE660
2011
-
Detection of CD4-Binding Site Antibodies in Three HIV-1 Seroconverter Cohorts
2011
-
Development of CAVD/EQAPOL Long-Term PBMC Repository ('07-'10) @ DUMC; T-Cell Functionality as Measured by ELISpot and Flow Cytometry Is Maintained Ov
2011
-
Efficacy of HIV Vaccine Candidate in Macaques Dependent on the Dose of SIVmac251 Challenge Exposure: Immune Correlates of Vaccine Efficacy
2011
-
HIV Neutralization in Breast Milk Mirrors that of Plasma and Is Mainly Mediated by IgG Antibodies
2011
-
HIV-1 gp120 V1V2-Scaffolds for Structural Analysis and Immunogen Design
2011
-
Identification of Amino Acid Residues in HIV-1 Envelope Targeted by Plasma Broadly Neutralizing Antibodies using Evolutionary Models
2011
-
Influence of NK Cells and NK Cell Receptor Polymorphisms in the Assessment of HIV-1 Neutralization
2011
-
Isolation of CD4-Binding Site and V2/V3 Conformational (Quaternary) Broadly Neutralizing Antibodies from the Same HIV-1 Infected African Subject
2011
-
Mapping of ADCC Activity: The A32 Conformational C1 Epitope is a Dominant Target for ADCC Antibodies in Chronically HIV-1 Infected Subjects
2011
-
Ontogeny of CD8+T Cells in Acute HIV-1 that Inhibit Autologous and Heterologous Transmitted/Founder (T/F) Viruses
2011
-
Ontogeny, Breadth, and Specificity of Circulating ADCC-Mediating Antibodies in HIV-1 Infected Individuals
2011
-
Profiles of Neutralizing Antibody Responses in Chronically HIV-1 CRF07_BC Infected Intravenous Drug Users in Western China
2011
-
Structural Basis for VRC01-Like-Antibody Recognition of Variable Loops that Surround the Site of CD4 Attachment on HIV-1 Gp120
2011
-
Structures of HIV-1 Quaternary-Structure-Preferring Antibodies, CH04 And PG9, Show Conserved Structural Elements Within a Generallly Flexible CDR H3
2011
-
Surface Plasmon Resonance Analysis of Anti-gp120 V2-Specific IgG Antibodies Generated in the RV144 Thai Trial
2011
-
The CD8+T Cell Antiviral Inhibitory Activity Predicts the Rate of CD4+Cell Decline in Early HIV-1 Infection and Is Independent of Viral Subtype
2011
-
Titered Mucosal Challenge of Rhesus Macaques with SIVmac251 Recapitulates HIV Vaccine Efficacy in Humans
2011
-
V2-Reactive Antibodies in RV144 Vaccinees' Plasma
2011
-
Whole Blood Transcriptional Monitoring of Acute HIV-1 Infection Reveals Differential Signatures of Host Immune Activation
2011
-
Antigenicity and immunogenicity of transmitted/founder HIV envelope oligomers compared to chronic HIV envelopes
2010
-
Computationally identified mutations suspected to cause gp120 charge inversion and gp41-mediated allosteric effects impact IgG1b12 susceptibility
2010
-
Crystal structure of a non-neutralizing antibody to the HIV-1 gp41 membrane proximal external region
2010
-
DNA and combination vaccines achieve high levels of long lasting and protective cellular and humoral responses
2010
-
Decrease in the Ratio of Infectious to Total Virions During Acute HIV-1 Infection
2010
-
Early Appearance of ADCC- and ADCVI-mediating Antibody Responses Against Autologous HIV-1 Transmitted/Founder Virus
2010
-
Early plasma B cell responses to transmitted HIV-1 are directed to envelope gp41 and originate by the activation of mutated B cell clones
2010
-
Effect of Fc gamma-receptor polymorphisms in rhesus macaques on SIVmac251 setpoint viremia
2010
-
Epitope Specificities of Elite Neutralizing Sera from HIV-1-Infected Individuals
2010
-
Evidence against phagocytosis in Fc gamma RI-mediated HIV neutralization by MPER antibodies in TZM-bl cells
2010
-
Evolution of the Same HIV-1 Transmitted/Founder Virus in Two Hosts
2010
-
Genome-Wide Significant Association of the GM 23 Allotype with gp120-Specific IgG2 Titers in an Efficacy Trial of AIDSVAX B/B
2010
-
Genome-wide Association Study for HIV-1 Heterosexual Acquisition and Plasma HIV Set Point Among African Serodiscordant Couples
2010
-
High magnitude and multifunctionality epitope-specific CD8+T-cell responses are associated are associated with selection of escape mutants in acute HIV infection
2010
-
High titers of cross-clade ADCC-mediating antibodies are detectable in plasma samples collected from individuals with broadly neutralizing antibodies
2010
-
Identification of B-chronic lymphocytic leukemia unmutated IgM germline antibodies that react with HIV-1 envelope gp41 epitopes
2010
-
Immunoregulation of HIV-1 broadly neutralizing antibody responses: deciphering maturation paths for antibody induction
2010
-
Improved DNA vaccination achieves long-lasting immune responses in macaques
2010
-
Improvement of humoral immune responses in macaques using DNA/viral particle combination vaccine
2010
-
Induction of antibodies with specificity for gp41 neutralizing epitopes by membrane anchored gp41 immunogens
2010
-
Isolation of Human Monoclonal Antibodies from HIV-Uninfected Subjects Immunized with gp120/NefTat/AS01B by Dual-Color Antigen-Specific B Cell Sorting
2010
-
Limited introductions and genetic variation of HIV-1 in a MSM cohort in China
2010
-
Local production of HIV variants in breast milk of chronically HIV-infected, lactating women
2010
-
Low Dose Mucosal SIV Infection Restricts Early Replication Kinetics and Transmitted Virus Variants in Rhesus Monkeys
2010
-
Magnitude and Breadth of the Neutralizing Antibody Response in RV144
2010
-
Molecular targets and potency of HIV-1 neutralization revealed by dynamic assessment of transmitted/founder virus antibody recognition and escape
2010
-
Neutralizing antibody responses to HIV-1 are dependent on conformational integrity of gp140 immunogens
2010
-
New broadly neutralizing human monoclonal antibodies targeting the 2F5 epitope
2010
-
Profiles of neutralizing antibody responses in chronically HIV-1 clade B' infected treatment-naive former plasma donors in China
2010
-
Rapid and high throughput strategy for expressing human monoclonal antibodies and generating of antibody-expression stably transfected cell lines
2010
-
Reverted unmutated ancestor 2F5 VH2-5 alleles differentially bind gp41 and bacterial proteins: a genetic basis for gp41 neutralizing B cell responses
2010
-
Role of immunoglobulin light chain usage and MPER specificity in counterselecting B cells expressing the broadly neutralizing antibody 2F5
2010
-
SIV-Specific Cytotoxic CD4+T Cells and Humoral Responses Control Rebounding Viremia in CD8-Depleted Macaques Infected with Rev-Independent SIV
2010
-
The B cell repertoire of terminal ileum in HIV-1 infection: concentration of antigen-reactive cells in the plasma cell versus the memory B cell pool
2010
-
Vaccine-Elicited IgG Subclasses and Functional Antibodies
2010
-
HTLV-II Establishes a Persistent Infection in Rhesus Macaques and Does Not Exacerbate SIV Infection
2009
-
2F5-Like Antibody Identified from an HIV-Infected Patient Concurrent with the Development of Autoimmune Antibodies
2008
-
All Known Cross-Reactive HIV-1 Neutralizing Antibodies are Highly Divergent from Germline and Their Elicitation May Require Prolonged Periods of Time
2008
-
Anti-lipid Human Monoclonal Antibodies Inhibit HIV-1 Infection of PBMC by Binding to Host Cells
2008
-
Characterisation of the Genetic Bottle-Neck in HIV-1 Subtype C, Heterosexually Infected Men and Women from Malawi and South Africa
2008
-
Covalent gp120 Immunization: Induction of Neutralizing Monoclonal Antibodies but Failure to Enhance Vaccine-Relevant Polyclonal Antibody Activity
2008
-
Detection of Cross-Clade T- and B-Cell-Mediated Immune Responses among HIV-1 Infected Individuals in Northern Tanzania
2008
-
Enhanced Neutralization of HIV-1 by gp41 MPER-Specific Antibodies in Cells that Express Fcg Receptors
2008
-
Establishing PBMC Repository for T Cell Assays Optimization and Proficiency Testing in CTC-VIMC Laboratories
2008
-
Exceptionally Potent, Broadly-Neutralizing IgAs from Survivors of Prolonged HIV Infection
2008
-
Functional Analysis of the Quasispecies env Population in Individuals Infected with HIV-1 Subtype C Viruses
2008
-
Functional Comparison of HIV-1 env Gene Quasispecies Populations from Acutely and Chronically Infected Individuals
2008
-
Generation of Robust Antibody Responses to HIV-1 Membrane Proximal External Region (MPER) Antigens
2008
-
HIV-1 Immune Complexes are part of the Initial B cell Response in Acute HIV-1 infection
2008
-
Highly Complex Neutralization Determinants on a Monophyletic Lineage of Newly Transmitted Subtype C HIV-1 Env Clones from India
2008
-
Identification of Transmitted/Founder Complete HIV-1 Genomes in Subjects with Acute HIV-1 Infection
2008
-
Immunogenicity and Neutralization Properties of a Trimeric MPER Containing gp41 Antigen
2008
-
Improved Induction of Antibodies against Key Neutralizing Epitopes by HIV-1 gp120 DNA Prime-Protein Boost Compared to gp120 Protein Only Vaccination
2008
-
Interferon-gamma Responses to HIV-1 Clade A and D Peptides in Ugandan Serodiscordant Couples - the CHAVI 002 Protocol
2008
-
Lack of Highly Poly-Functional Epitope-Specific CD8+Memory T Cell Responses during Spontaneous Control of Viremia
2008
-
Microparticles and Apoptotic Cells Generated from Apoptotic T Cells Inhibit Human Dendritic Cell Cytokine Production
2008
-
Pattern of HIV-1-gp41 Binding and Neutralizing Antibodies in Subtype C Infected Women and in their HIV-1-Seronegative Neonates
2008
-
Perturbations of the Vb-T Cell Repertoire in HIV Uninfected Neonates Born to HIV-1 Subtype C Infected Mothers: Evidence for T Cell Priming in Utero
2008
-
Profile of HIV-1-env Binding and Neutralizing Antibodies in Subtype C, A and B Infected Women
2008
-
Recombination of HIV-1 gp160 Clones with Viral Backbone DNA through Co-transfection to Produce Pseudoviruses can Create Replication Competent Viruses
2008
-
T Cell Escape in Subjects with Acute HIV-1 Infection
2008
-
The Role of Lipid Reactivity of HIV-1 gp41 Membrane Proximal Antibodies in Neutralization of HIV-1: Novel Liposome Based Immunogen Design
2008
-
Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies.
1999
-
AN ENV GENE DERIVED FROM A PRIMARY HIV-1 ISOLATE CONFERS HIGH IN-VIVO REPLICATIVE CAPACITY TO A CHIMERIC SIMIAN/HUMAN IMMUNODEFICIENCY VIRUS IN RHESUS-MONKEYS
1995
-
HIV-1 SPECIFIC CTL RESPONSES AMONG RECIPIENTS OF CANDIDATE AIDS VACCINES
1995
-
PRIMARY IMMUNE-RESPONSE TO HIV-INFECTION
1995
-
SIV PATHOGENESIS DURING ONTOGENY - THE VIRUS THRESHOLD HYPOTHESIS
1995
-
SUPPRESSION OF HIV-1 REPLICATION BY PRIMARY AND TRANSFORMED CD8 CELLS
1995
-
WHAT IS THE FATE OF COMPLEMENT-OPSONIZED HIV
1995
-
ANTIVIRAL ACTIVITY AND MECHANISM OF INHIBITION OF GP41 DERIVED SYNTHETIC PEPTIDES
1994
-
BINDING OF HIV-1 TO THE C3B/C4B RECEPTOR, CR-1 (CD35), IN THE PRESENCE OF COMPLEMENT AND ANTIBODIES FROM INFECTED INDIVIDUALS AND GP160-VACCINATED VOLUNTEERS
1994
-
CD8+T-LYMPHOCYTE-MEDIATED INHIBITION OF HIV-1 LTR TRANSCRIPTION
1994
-
DIRECT GENE-TRANSFER AND MOLECULAR INTERVENTIONS FOR AIDS AND CANCER
1994
-
CYTOTOXIC T-LYMPHOCYTE REACTIVITIES AMONG HIV-1 VACCINE RECIPIENTS IN THE AIDS VACCINE EVALUATION NETWORK
1994
-
MECHANISM OF RESISTANCE OF HIV-1 AND SIV TO COMPLEMENT LYSIS - THE ROLE OF ANTI-CELL ANTIBODIES IN VACCINE PROTECTION
1994
-
Preparatory studies for possible HIV vaccine trials in northern Thailand.
1994
-
SEROLOGICAL REACTIVITY FROM HIV-1 VACCINE RECIPIENTS PARTICIPATING IN THE AIDS VACCINE CLINICAL-TRIALS NETWORK
1994
-
V3-SPECIFIC NEUTRALIZING ANTIBODIES IN SERA FROM HIV-1 GP160-IMMUNIZED VOLUNTEERS BLOCK VIRUS ATTACHMENT AND ACT SYNERGISTICALLY WITH HUMAN MONOCLONAL-ANTIBODY TO THE CONFORMATION-DEPENDENT CD4 BINDING REGION OF GP120
1993
-
CHANGES IN THE ENVELOPE GLYCOPROTEINS ARE ASSOCIATED WITH INFECTIVITY OF SIV AND DOWN-MODULATION OF CD4
1992
-
COMPARISON OF CELLULAR ANTIVIRAL CYTOTOXICITIES PRESENT IN HIV-1 INFECTED HUMANS AND CHIMPANZEES
1992
-
COMPLEMENT-MEDIATED, INFECTION-ENHANCING ANTIBODIES IN HIV AND SIV INFECTION AND VACCINE TRIALS
1992
-
PH-INDEPENDENT HIV-1 ENTRY INTO MACROPHAGE
1992
-
THE ENVELOPE V3 LOOP IS THE PRIMARY DETERMINANT OF CELL TROPISM IN HIV-1
1992
-
EVALUATION OF V3 REGION BASED SYNTHETIC PEPTIDE INOCULA AS VACCINES FOR HIV-1 AND SIV
1990
-
HTLV REACTIVITY IN NORMAL POPULATION OF SOUTHERN APULIA (ITALY)
1990